A phase II study of KOS-862, administered intravenously weekly for 3 weeks every 4 weeks, in patients with non-small cell lung cancer who have progressed following initial therapy for advanced or metastatic disease.

Trial Profile

A phase II study of KOS-862, administered intravenously weekly for 3 weeks every 4 weeks, in patients with non-small cell lung cancer who have progressed following initial therapy for advanced or metastatic disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2010

At a glance

  • Drugs Epothilone D (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Feb 2010 Status changed from discontinued to completed as reported by Roche record.
    • 13 Jul 2007 New trial record.
    • 23 Nov 2004 Primary endpoint 'Objective clinical response rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top